CryositeASX:CTE 51 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 55 Medical Diagnostics & Research companies, Cryosite ranks better than 54.55% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Cryosite's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Cryosite's Dividend Payout Ratio or its related term are showing as below:
ASX:CTE'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.35 Med: 1.67 Max: 2
Current: 0.47
During the past 13 years, the highest Dividend Payout Ratio of Cryosite was 2.00. The lowest was 0.35. And the median was 1.67.
ASX:CTE's Dividend Payout Ratio is ranked better than 54.55% of 55
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.49
vs ASX:CTE: 0.47
During the past 12 months, Cryosite's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Cryosite was 44.20% per year. The lowest was -12.60% per year. And the median was 0.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Cryosite (ASX:CTE) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cryosite Dividend Payout Ratio Related Terms
Cryosite Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Cryosite's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: Dividend Payout Ratio Comparison
For the Diagnostics & Research subindustry, Cryosite's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Dividend Payout Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Cryosite's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Cryosite's Dividend Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Cryosite and its competitors. Over the past decade, Cryosite's Dividend Payout Ratio has ranged from 0.35 to 2.00. According to the industry distribution chart, Cryosite ranks #25 out of 55 companies in the Medical Diagnostics & Research industry, placing it in the top 45.5%.
Is Cryosite's Dividend Payout Ratio too high?
Cryosite's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 2.00. Based on the distribution chart, Cryosite ranks #25 out of 55 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Dividend Payout Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #25 out of 55 companies for Dividend Payout Ratio. This puts Cryosite in the upper half of its industry. The industry median Dividend Payout Ratio is 0.49. Historically, Cryosite's own Dividend Payout Ratio has ranged from 0.35 to 2.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Diagnostics & Research company?
The median Dividend Payout Ratio among Medical Diagnostics & Research companies is 0.49, based on 55 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Payout Ratio is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
Dividend Payout Ratio: 0.00
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
